TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--We are excited to share our latest development status. We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback